You are here

Home » Content

RADYOİYOT İLE HİPERTİROİDİ TEDAVİSİ SONUÇLARIMIZ

The outcome of the treatment of hyperthyroidism with radioiodine

Journal Name:

  • Selçuk Tıp Dergisi

Publication Year:

  • 2007

Key Words:

Keywords (Original Language):

Author NameUniversity of Author
Abstract (2. Language): 
Aim: Radioiodine treatment with iodine-131 (1-131) is a preferable treatment modality in the hyper-thyroidism such as Graves' disease, nodular and multinodular goitre. 1n this retrospective study, we aimed to report short-term results of the hyperthyroid patients admitted to our clinic. Material and Method: Two hundreds and seventy patients admitted to Meram Medical Faculty, Department of Nuclear Medicine from December 2001 to March 2005 was included the study. The diagnosis was Graves' disease (GD) in 155 (57%), toxic adenoma (TA) in 46 (17%) and toxic multinodular goitre (TMNG) in 69 (26%). The dose administered to patients with GD was 5-28 mCi (mean 10,58 ± 3,43), TA was 6-25 mCi (mean 11,78 ± 3,93), and TMNG was 5-30 mCi (mean 12,13 ± 3,03).Results: After the mean 8,16 ± 7,40 months follow-up, 87 patients (32,2%) were hyperthyroid, 104 (38,5%) were euthyroid, and 79 (29,3%) were hypothyroid. The response of treatment in the long period follow-up was better than short period one. It was determined that the responded group has been followed-up the longer period than the non-responded group (9,10 ± 7,76 months vs 6,17 ± 6,15 months). Mean age of the responded group is 52,09 ± 12,56 years, the other is 56,16 ± 15,38. The difference is significant. Conclusion: In our opinion, the response rate of I-131 therapy would increase in the long term follow-up of hyperthyroid patients.
Bookmark/Search this post with
Abstract (Original Language): 
Amaç: İyot-131 (1-731) ile radyoiyot tedavisi, hipertiroidi ile seyreden Graves hastalığı, nodüler ve multinodüler guatrın tedavisinde tercih edilen yöntemlerden biridir. Bu retrospektif çalışma ile, radyo¬iyot verip takibimiz altında bulunan hipertiroidi hastalarının kısa dönem sonuçlarını ortaya koymayı amaçladık. Gereç ve Yöntem: Aralık 2001-Mart 2005 tarihleri arasında SÜ Meram Tıp Fakültesi Nükleer Tıp Kliniğinde hipertiroidi nedeniyle radyoiyot tedavisi alıp, takibimiz altında bulunan 270 hasta çalışmaya dahil edildi. Hastaların 155'inin tanısı (% 57) Graves' hastalığı (GH), 46'sının (% 17) toksik adenom (TA), 69'unun ise (% 26) toksik multinodüler guatrdı (TMNG). GH'da verilen doz 5-28 mCi (ortalama 10,58 ± 3,43), TA'da 6-25 mCi (ortalama 11,78 ± 3,93), TMNG'da ise 5-30 mCi (orta¬lama 12,13 ± 3,03) arasındaydı. Bulgular: Ortalama 8,16 ± 7,40 aylık takip sonunda hastalardan 87'si (%32,2) hipertiroid kalırken, 104'ü (% 38,5) ötiroid, 79'u (% 29,3) ise hipotiroid oldu. Tedaviye yanıt alınan grubun, yanıt alınmayan gruba göre daha uzun süre takip edildiği tespit edildi (9,10 ± 7,76 ay, 6,17 ± 6,15 ay). Tedaviye cevap veren grupta ortalama yaş 52,09 ± 12,56, cevap vermeyen grupta ortalama yaş 56,16 ± 15,38 olarak bulunmuş olup yaş ortalamaları arasındaki fark anlamlıdır. Sonuç: Takip süresi uzadıkça, 1-131 ile hipertiroidi tedavisinde başarı oranlarımızın yükseleceği kanaatindeyiz.
FULL TEXT (PDF): 
PDF icon arastirmax-radyoiyot-ile-hipertiroidi-tedavisi-sonuclarimiz.pdf
  • 1
1-5
  • Turkish

REFERENCES

References: 

1. Tuttle RM, Becker DV, Hurley JR. Radioiodine treat¬ment of thyroid disease. In: Sandler MP, ed. Diag¬nostic nuclear medicine. USA: Lippincott WW; 2003:653-70.
2. Wilson MA. Thyroid and thyroid therapy. In: Wil-son MA, ed. Textbook of nuclear medicine. USA: Lippincott-Raven; 1998:153-87.
3. Freitas JE. Therapetic options in the management of toxic and nontoxic nodular goiter. Semin Nucl
Med 2000;30:88-97.
4. Özdogan Ö, Argon M, Atasever T, Çelen YZ, Kaba¬sakal L, Karayalçın B, et al. I-131 ile hipertiroidizm tedavisi uygulama kılavuzu. Turk J Nucl Med
2001;10:S29-S32.
5. Hatemi HH. Türkiye'de guatr epidemiyolojisi. En-dokrinolojide Yönelişler 2005;14:139-44.
6. Erem C. Hipertiroidi ve tedavisi. Endokrinolojide Yönelişler 2005;14:145-68.
7. Cappelen T, Unhjem JF, Amundsen AL, Kravdal G, Felling I. Radiation exposure to family members of patients with thyrotoxicosis treated with iodine-131. Eur J Nucl Med Imaging 2006;33:81-6.
8. Howarth D, Epstein M, Lan L, Tan P, Booker J. De-termination of the optimal minimum radioiodine dose in patients with Graves' disease: A clinical outcome study. Eur J Nucl Med 2001;28:1489-95.
9. Metso S, Jaatinen P, Huhtala H, Luukkaala T, Ok-sala H, Salmi J. Long-term follow-up study of radi-oiodine treatment of hyperthyroidism. Clin Endoc-rinol (Oxf) 2004;61:641-8.

10. Giovanella L, De Palma D, Ceriani L, Vanoli P, Ga-rancini S, Tordiglione M, et al. Radioiodine treat¬ment of hyperthyroidism using a simplified dosi-metric approach. Clinical results. Radiol Med (Tori¬no) 2000;100:480-3.
11. Erdoğan MF, Küçük NÖ, Anıl C, Aras S, Özer D, Aras G, et al. Effect of radioiodine therapy on thyroid nodule size and function in patients with toxic adenomas. Nucl Med Commun
2004;25:1083-7.
12. Tajiri J. Radioiodine treatment in patients with Gra¬ves' disease at outpatient clinic: Special reference to safety and short-term outcome. Kaku Igaku
2005;42:115-22.
13. Rivkees S. Editorial: Radioactive iodine use of childhood Graves' disease: Time to wake up and smell the I-131. J Clin Endocrinol Metab
2004;89:4227-8.
14. Leu SW, Chi CS, Shu SG. Outcome of antithyroid medication and radioiodine therapy in pediatric Graves' disease. Acta Paediatr Taiwan
2003;44:220-6.
15. Read CH, Tansey MJ Jr, Menda Y. A 36-year retros¬pective analysis of the efficacy and safety of radioactive iodine in treating young Graves'
patients. J Clin Endocrinol Metab 2004;89:4229-33.

Thank you for copying data from http://www.arastirmax.com